John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.
John Leonard, MD
Advertisement
Articles by John Leonard, MD
John P. Leonard, MD, discusses the potential for combination regimens with PI3K inhibitors in follicular lymphoma.
John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses follicular lymphoma treatment considerations. Treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma
2
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
3
STRIDE Plus TACE With/Without Lenvatinib Improves Responses in Embolization-Eligible HCC
4
INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer
5